Bloomberg Quint

Share

Bloomberg Quint

 •  January 13

(Bloomberg) -- India’s proposal to curb drug prices by stripping generic medicines of their brand names has stalled after the plan faced pushback from the country’s pharmaceutical companies, according to people with knowledge of the discussions. The Draft Pharmaceutical Policy circulated last summer by the Department of Pharmaceuticals has made no...

Bloomberg Quint

 •  January 8

(Bloomberg) -- Celgene Corp. agreed to buy closely held Impact Biomedicines for $1.1 billion upfront to gain an experimental blood cancer treatment. The price could reach as much as $7 billion over time if the drug reaches certain milestones. Under the agreement, Celgene will add up to $1.25 billion to the upfront payment if Impact’s drug...

Bloomberg Quint

 •  January 3

Shares of the Hyderabad-based Neuland Laboratories Ltd. have the potential to gain almost 50 percent this year. That's according to analysts tracked by Bloomberg. The drugmaker, which specialises in bulk drugs and intermediates, has a market capitalisation of Rs 781 crore and a consensus target price of Rs 1,312.5, Bloomberg data showed. It rose as...

Bloomberg Quint

 •  January 2

Manufacturing tests are used to make sure drugs are sterile and free of contaminants. At Fresenius’s Baddi, India, facility workers had a history of invalidating the quality tests when a negative result was found, the Food and Drug Administration said in a Dec. 18 warning letter to the company. The FDA said the company had failed to adequately...

Bloomberg Quint

 •  December 27, 2017

(Bloomberg) -- U.S. regulators warned Fresenius SE after the company’s Indian plant that makes cancer-drug ingredients for the U.S. market aborted hundreds of drug-quality tests because they seemed like they were going to fail due to impurities. When workers at the plant found potential tainted products, they halted the tests and said human or...

Bloomberg Quint

 •  November 24, 2017

The National Pharmaceutical Pricing Authority today said it has capped prices of 51 essential drug formulations, including those used for the treatment of cancer, pain, heart conditions and skin problems. In separate notifications, the drug price regulator said it has notified ceiling prices of 13 formulations, while revising the same for 15...